<PAGE> 1
- --------------------------------------------------------------------------------
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
------------------------------
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO SECTION 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
For the month of September 1999.
PROTEUS INTERNATIONAL PLC
(Translation of Registrant's Name Into English)
Beechfield House
Lyme Green Business Park
Macclesfield Cheshire SK11 0JL
England
(Address of Principal Executive Offices)
(Indicate by check mark whether the registrant files or will file
annual reports under cover of Form 20-F or Form 40-F.)
Form 20-F [X] Form 40-F [ ]
(Indicate by check mark whether the registrant by furnishing the
information contained in this form is also thereby furnishing the information to
the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of
1934.)
Yes [ ] No [X]
(If "Yes" is marked, indicate below the file number assigned to the
registrant in connection with Rule 12g3-2(b): 82-________________.
Attached to the Registrant's Form 6-K for the month of September 1999
and incorporated by reference herein is the Registrant's announcement, dated
September 13, 1999, filed with the Company Announcements Office of the London
Stock Exchange.
<PAGE> 2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
PROTEUS INTERNATIONAL PLC
Date: September 13, 1999 By: /s/ Barrington M. Riley
---------------------------------
Barrington M. Riley
Finance Director
<PAGE> 3
Proteus International Plc ("Proteus" or the "Company")
Result of the Extraordinary General Meeting (the "EGM")
The Board of Proteus announces that at the EGM held earlier today, all
resolutions, including the resolution to approve the proposed merger with
Therapeutic Antibodies Inc ("Therapeutic Antibodies"), (the "Merger"), the
resolution to approve the allotment of new Ordinary shares pursuant to the
Merger and Placing and the resolution to change the name of the Company to
Protherics PLC, were duly passed.
It is expected that completion of the Merger will occur at 9 am on 15 September
1999, when it is expected that dealings in the new Protherics PLC Ordinary
Shares will commence. Also at that time it is expected that the cancellation of
the listing of Therapeutic Antibodies' common stock on the London Stock Exchange
will become effective.
13 September 1999
